Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
UNIKUM Therapeutics ApS
APS
Active
Advertising protection
CVR 41192925
Kanehaven 33, 8240
Risskov
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2020 · 6 years old
2 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
UNIKUM Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
-2M
-4M
-7M
-9M
2021: -3M
-3M
2021
2022: -3M (0% vs 2021)
-3M
0%
2022
2023: -7M (-133% vs 2022)
-7M
-133%
2023
2024: -7M (0% vs 2023)
-7M
0%
2024
2025: 0M (+100% vs 2024)
0M
2025
EBITDA
DKK millions
0M
-5M
-9M
-14M
-19M
2021: -6M
-6M
2021
2022: -8M (-33% vs 2021)
-8M
-33%
2022
2023: -15M (-87% vs 2022)
-15M
-87%
2023
2024: -15M (0% vs 2023)
-15M
0%
2024
2025: 0M (+100% vs 2024)
0M
2025
Income statement
DKK thousands
Item
2025
2024
2023
2022
2021
Gross profit
-248
-7.368
-7.465
-3.315
-2.726
Staff expenses
-114
-7.888
-7.895
-4.853
-3.685
EBITDA
-362
-15.257
-15.361
-8.168
-6.411
Depreciation & amort.
-0
-0
-14
-16
-16
EBIT
-362
-15.257
-15.375
-8.184
-6.427
Net financials
-534
-657
-1.351
-719
-601
Profit before tax
-895
-15.914
-16.726
-8.903
-7.028
Tax
-36
-2.117
-1.855
-1.255
-1.473
Net profit
-859
-13.797
-14.871
-7.649
-5.555
Balance sheet
DKK thousands
Item
2025
2024
2023
2022
2021
Total assets
138
3.759
3.996
3.057
6.700
Equity
-5.680
-4.821
-16.284
-15.294
-7.645
Long-term debt
5.507
4.040
18.555
17.282
13.600
Short-term debt
311
4.540
1.726
1.069
745
Total debt
5.818
8.580
20.280
18.351
14.345
Financial ratios
5-year trend
EBITDA margin (of gross profit)
<−999 %
This company
2021
2025
Equity ratio
<−999 %
This company
38,2 %
Market median
This company
Market median
>999% below market
2021
2025
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2021
2025
Net profit margin (of gross profit)
<−999 %
This company
2021
2025
Asset turnover (of gross profit)
-1,80×
This company
2021
2025
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on UNIKUM Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
